Revance Logo
COMPANYPRODUCTS AND PIPELINEINVESTORSCAREERSIN THE NEWSCONTACT US
ABOUTLEADERSHIPBOARDPARTNERSHIPS
SUSTAINABILITYMEDICAL EDUCATIONAL GRANTSINVESTIGATOR SPONSORED TRIALS
Company
INVESTOR RELATIONSPRESS RELEASESEVENTS + PRESENTATIONSFINANCIALS & FILINGSCORPORATE GOVERNANCE
STOCK INFORMATIONANALYST COVERAGEINVESTOR FAQSCONTACT US
Investors
OPPORTUNITIESCULTUREBENEFITS
Careers
COMPANYPRODUCTS AND PIPELINEINVESTORSCAREERSIN THE NEWSCONTACT US
Facebook logoInstagram logoTwitter logoLinkedIn logo
1222 Demonbreun St
20th Floor
Nashville, TN 37203
+1 (510) 742-3400
LoginContact Revance
Back
May 29, 2018
Revance to Participate in the Jefferies 2018 Global Healthcare Conference
May 29, 2018
Revance Announces Departure of Chief Financial Officer
May 24, 2018
Revance Announces Publication of Positive 24-Week Duration of Effect Results from Cervical Dystonia Phase 2 Trial in Movement Disorders Clinical Practice
May 15, 2018
Revance to Participate in the UBS Global Healthcare Conference
May 9, 2018
Revance Therapeutics Announces Two Recent Additions to Its Management Team
May 8, 2018
Revance Releases First Quarter 2018 Results
May 1, 2018
Revance Therapeutics Expands Leadership Team, Appointing Caryn McDowell as SVP, General Counsel & Corporate Secretary
April 25, 2018
Pivotal SAKURA Phase 3 Clinical Data to be Featured in Oral and Poster Presentations at The Aesthetic Meeting 2018
April 24, 2018
Revance Therapeutics to Release First Quarter 2018 Financial Results on Tuesday, May 8, 2018
April 19, 2018
Revance Investor Day Highlights New Neuroscience Indications in Development
Displaying 141 - 150 of 278